Analysts expect IDEXX Laboratories, Inc. (NASDAQ:IDXX) to post $491.02 million in sales for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for IDEXX Laboratories’ earnings. The highest sales estimate is $494.68 million and the lowest is $487.10 million. IDEXX Laboratories reported sales of $443.00 million in the same quarter last year, which would suggest a positive year over year growth rate of 10.8%. The company is expected to announce its next quarterly earnings results before the market opens on Thursday, February 1st.
According to Zacks, analysts expect that IDEXX Laboratories will report full-year sales of $491.02 million for the current year, with estimates ranging from $1.95 billion to $1.96 billion. For the next financial year, analysts anticipate that the business will post sales of $2.16 billion per share, with estimates ranging from $2.14 billion to $2.18 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for IDEXX Laboratories.
IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Tuesday, October 31st. The company reported $0.79 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.74 by $0.05. IDEXX Laboratories had a negative return on equity of 336.64% and a net margin of 14.55%. The business had revenue of $492.00 million for the quarter, compared to the consensus estimate of $492.94 million. During the same period in the previous year, the company posted $0.62 earnings per share. The company’s revenue for the quarter was up 9.7% compared to the same quarter last year.
Shares of IDEXX Laboratories (NASDAQ IDXX) opened at $180.63 on Friday. The company has a quick ratio of 0.77, a current ratio of 0.95 and a debt-to-equity ratio of -12.48. IDEXX Laboratories has a 1-year low of $116.54 and a 1-year high of $180.88. The company has a market capitalization of $15,754.37, a price-to-earnings ratio of 58.46, a price-to-earnings-growth ratio of 2.43 and a beta of 0.42.
In related news, insider Giovani Twigge sold 2,000 shares of the company’s stock in a transaction on Thursday, November 30th. The stock was sold at an average price of $156.07, for a total transaction of $312,140.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Jonathan W. Ayers sold 2,160 shares of the company’s stock in a transaction on Thursday, January 11th. The shares were sold at an average price of $167.03, for a total value of $360,784.80. Following the sale, the chief executive officer now owns 1,077,112 shares of the company’s stock, valued at approximately $179,910,017.36. The disclosure for this sale can be found here. Insiders sold 130,160 shares of company stock valued at $20,019,685 in the last 90 days. Company insiders own 2.77% of the company’s stock.
A number of institutional investors have recently bought and sold shares of IDXX. Koch Industries Inc. increased its position in IDEXX Laboratories by 44,533.1% during the second quarter. Koch Industries Inc. now owns 1,399,248 shares of the company’s stock valued at $1,391,000 after acquiring an additional 1,396,113 shares during the last quarter. Janus Henderson Group PLC increased its position in IDEXX Laboratories by 486.4% during the second quarter. Janus Henderson Group PLC now owns 1,131,902 shares of the company’s stock valued at $182,711,000 after acquiring an additional 938,888 shares during the last quarter. Atlantic Trust Group LLC purchased a new stake in IDEXX Laboratories during the third quarter valued at $65,381,000. Arrowstreet Capital Limited Partnership increased its position in IDEXX Laboratories by 42.8% during the second quarter. Arrowstreet Capital Limited Partnership now owns 1,310,660 shares of the company’s stock valued at $211,567,000 after acquiring an additional 392,790 shares during the last quarter. Finally, Renaissance Technologies LLC increased its position in IDEXX Laboratories by 38.6% during the second quarter. Renaissance Technologies LLC now owns 1,351,900 shares of the company’s stock valued at $218,224,000 after acquiring an additional 376,300 shares during the last quarter. Institutional investors own 86.66% of the company’s stock.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.